Ads
related to: pfizer
Search results
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 18 hours agoPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock was trading at $52 in early June 2022, just before ...
Kansas Attorney General sues Pfizer for misleading covid claims
KOAM· 6 hours ago(KANSAS) -- Kansas Attorney General Kris Kobach is suing Pfizer for misleading claims made related to the COVID vaccine.
Gateway - Quartz
Quartz· 2 hours agoThe company announced on Oct. 20 that it intends to sell the covid vaccine, marketed under the brand name Comirnaty, for $110 to $130 per dose. According to The People’s Vaccine Alliance, a ...
Is this the Time to Initiate a Pfizer (PFE) Position?
Insider Monkey via Yahoo Finance· 6 days agoDiamond Hill Capital, an investment management company, released its “Select Strategy” first-quarter...
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia,...
NBC New York· 2 hours agoThe Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via Yahoo News· 5 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
US FDA approves Merck's pneumococcal vaccine for adults
Reuters· 57 minutes ago, opens new tab said on Monday the U.S. Food and Drug Administration has approved its...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 4 days agoWho should wait, and who should get vaccinated now? The CDC advises that everyone ages 5 and older...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 5 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 3 days agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
